TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer : Stage-Matched Analysis of a Large Multicenter National Cohort
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses. Materials and Methods Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted. Results UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients. Conclusion Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.
Abstract
Purpose Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses. Materials and Methods Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted. Results UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients. Conclusion Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.
참고문헌 (20)
- Paner GP, "Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms : diagnostic implications and pitfalls", Am J Surg Pathol, 35, pp.787~798 (2011)
- Bruins HM, "The clinical epidemiology of urachal carcinoma : results of a large, population based study", J Urol, 188, pp.1102~1107 (2012)
- Szarvas T, "Clinical, prognostic, and therapeutic aspects of urachal carcinoma : a comprehensive review with meta-analysis of 1, 010 cases", Urol Oncol, 34, pp.388~398 (2016)
- Wright JL, "Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder", Cancer, 107, pp.721~728 (2006)
- Cho SY, "Outcomes of Korean patients with clinically localized urachal or non-urachal adenocarcinoma of the bladder", Urol Oncol, 31, pp.24~31 (2013)
- Luzzago S, "Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder", World J Urol, 38, pp.2819~2826 (2020)
- Wang T, "Survival of patients with UrAC and primary BAC and urothelial carcinoma with glandular differentiation", Front Oncol, 12, pp.860133~ (2022)
- Sheldon CA, "Malignant urachal lesions", J Urol, 131, pp.1~8 (1984)
- Ashley RA, "Urachal carcinoma : clinicopathologic features and long-term outcomes of an aggressive malignancy", Cancer, 107, pp.712~720 (2006)
- Hamilou Z, "Management of urachal cancer : a consensus statement by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada", Can Urol Assoc J, 14, pp.E57~64 (2020)
- Kakizoe T, "Ade-nocarcinoma of urachus : report of 7 cases and review of literature", Urology, 21, pp.360~366 (1983)
- Henly DR, "Urachal cancer : role of conservative surgery", Urology, 42, pp.635~639 (1993)
- Molina JR, "Predictors of survival from urachal cancer : a Mayo Clinic study of 49 cases", Cancer, 110, pp.2434~2440 (2007)
- Behrendt MA, "Urachal cancer : contemporary review of the pathological, surgical, and prognostic aspects of this rare disease", Minerva Urol Nefrol, 68, pp.172~184 (2016)
- Claps M, "Current understanding of urachal adenocarcinoma and management strategy", Curr Oncol Rep, 22, pp.9~ (2020)
- Jia Z, "Urachal carcinoma: are lymphadenectomy and umbilectomy necessary?", Med Sci Monit, 26, pp.e927913~ (2020)
- Karl A, "The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer", Eur Urol, 55, pp.826~835 (2009)
- Duan F, "Urachal carcinoma : Impact of recurrence pattern and lymphadenectomy on long-term outcomes", Cancer Med, 9, pp.4166~4174 (2020)
- Grignon DJ, "Primary adenocarcinoma of the urinary bladder : a clinicopathologic analysis of 72 cases", Cancer, 67, pp.2165~2172 (1991)
- Dhillon J, "Urachal carcinoma : a pathologic and clinical study of 46 cases", Hum Pathol, 46, pp.1808~1814 (2015)